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Abstract: Amyloid fibril formation occurs from a wide range of peptides and proteins and is typically
associated with a loss of protein function and/or a gain of toxic function, as the native structure of
the protein undergoes major alteration to form a cross β-sheet array. It is now well recognised that
some amyloid fibrils have a biological function, which has led to increased interest in the potential
that these so-called functional amyloids may either retain the function of the native protein, or gain
function upon adopting a fibrillar structure. Herein, we investigate the molecular chaperone ability
of α-crystallin, the predominant eye lens protein which is composed of two related subunits αA-
and αB-crystallin, and its capacity to retain and even enhance its chaperone activity after forming
aggregate structures under conditions of thermal and chemical stress. We demonstrate that both
eye lens α-crystallin and αB-crystallin (which is also found extensively outside the lens) retain,
to a significant degree, their molecular chaperone activity under conditions of structural change,
including after formation into amyloid fibrils and amorphous aggregates. The results can be related
directly to the effects of aging on the structure and chaperone function of α-crystallin in the eye
lens, particularly its ability to prevent crystallin protein aggregation and hence lens opacification
associated with cataract formation.
Keywords: amyloid fibril; small heat-shock protein; molecular chaperone; protein unfolding;
protein aggregation
1. Introduction
The crystallin proteins are primarily found within the mammalian eye lens where they form part
of the protein array that focuses light onto the retina via a supramolecular, liquid-like order [1–3].
Crystallins are highly stable proteins, as there is very limited protein turnover in the lens, particularly
in its centre [4,5]. α-crystallin, the predominant protein of the human lens, is a heterogeneous oligomer
comprised of two closely related subunits, αA- and αB-crystallin, in a ratio of approximately 3:1,
respectively [6]. α-crystallin oligomers are composed of between 15 and 50 of these subunits and
have an average mass of approximately 700 kDa [7,8]. The two α-crystallin subunits are members
of the small heat-shock protein (sHsp) family of molecular chaperone proteins. In the eye lens, their
chaperone action is important in maintaining the stability and solubility of other crystallin proteins.
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αB-crystallin (HSPB5), but not αA-crystallin (HSPB4), is also found in many other tissues where it
performs a variety of roles in protein stabilisation [9–11].
The identification of αB-crystallin in amyloid fibril deposits associated with a number of
neurodegenerative diseases, e.g., Alzheimer’s and Parkinson’s, suggests that the protein may
play a role in their progression by acting to prevent protein aggregation leading to amyloid fibril
formation [9,10,12,13]. As a result, significant research activity has been undertaken into the mechanism
by which αA- and αB-crystallin act as chaperones, both as homo- and hetero-oligomers. Delineation
of the means by which sHsps act as chaperones could have significant potential therapeutically.
Chaperone activity is proposed to involve mainly hydrophobic interactions between the accessible
hydrophobic region(s) on the chaperone and the exposed hydrophobic core of the unfolding target
protein [14–16]. The exact role hydrophobicity plays in chaperone-related interactions between
amorphously aggregating target proteins and α-crystallin is unclear. Potential chaperone binding
sites have been identified for αA- and αB-crystallin [17–22]. The interaction and complexation of
these chaperones with partially folded target proteins acts to stabilize the target protein, preventing
its aggregation and precipitation and, in vivo, potentially staves off disease states that arise due to
unfolding and mis-folding of such proteins.
As implied from their name, sHsp expression is elevated under conditions of thermal cellular
stress [23]. At elevated temperatures, the structure of α-crystallin is altered due to partial unfolding
and a subsequent enhancement in chaperone activity occurs. αA-crystallin in particular has increased
chaperone efficiency at elevated temperature [24,25] which is postulated to be linked to an increase
in exposed hydrophobicity at temperatures above 50 ◦C [6]. αB-rystallin also retains its ability to act
as a chaperone at temperatures above 60 ◦C [24,25]. Thermal stress is not the only situation that may
lead to increased chaperone activity of α-crystallin. Das and Liang [26] demonstrated that α-crystallin,
when unfolded by guanidine hydrochloride (GdnHCl), forms a molten globule (intermediate) state
with enhanced chaperone ability. They argued that such intermediate forms of α-crystallin would
occur in vivo due to post-translational modifications, such as glycation, oxidation and mixed disulfide
formation. From the above, it is apparent that αA- and αB-crystallin act effectively as molecular
chaperones under conditions of cellular stress (i.e., during heat shock) even when their structure is
disrupted or partially unfolded [27,28].
Concomitant with α-crystallin’s thermally enhanced chaperone ability is an increase in size of the
α-crystallin oligomer, i.e., the diameter of the α-crystallin oligomer increases from 14.7 ± 2.7 nm at
35 ◦C to 26.8 ± 4.3 nm at 60 ◦C [29]. The enhanced chaperone activity is proposed to be associated with
increased hydrophobicity of α-crystallin under thermal stress, rather than to be linked to oligomer
size [16]. An increase in subunit exchange is also proposed to be a factor in the enhanced chaperone
activity of α-crystallin at higher temperature [18]. The ability of urea-denatured α-crystallin to refold
into smaller oligomers that exhibit an increased chaperone activity is consistent with these factors [30].
However, cross-linked α-crystallin retains chaperone activity [31,32], implying that the dissociated
(probably dimeric) form of α-crystallin is not entirely responsible for the chaperone action of the
protein, i.e., the oligomeric form retains at least some chaperone activity.
In contrast to amorphous aggregation, amyloid fibril formation results in the protein being
rearranged into a well-ordered cross β-sheet fibrillar structure [33,34]. Amyloid fibrils are frequently
associated with cellular damage in vivo, due to the formation of toxic precursors and the deposition of
large conglomerates known as amyloid plaques composed primarily of amyloid fibrils [35]. Amyloid
fibrils are a structure potentially accessible to all proteins and can be formed in vitro from proteins not
associated with disease [36]. As well as being highly ordered, amyloid fibrils are thermodynamically
stable and are resistant to proteolysis, dehydration and extremes of pH, temperature or pressure [37–40].
The identification of biologically active amyloid species, known as functional amyloid, has increased
the interest in the potential uses of such a stable core structure of proteins for a wide variety of
applications [36,41–43].
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Protein aggregation and sHsp chaperone activity can be studied in vitro under a variety of
conditions related to the properties of the aggregating protein and the type of aggregation it undergoes
(either amorphous or amyloid fibrillar) [22,44]. Herein, a range of target proteins and destabilisation
techniques were used, providing a comprehensive picture of α-crystallin chaperone activity in its
various aggregation states, i.e., the native, amorphous and amyloid fibrillar forms. The results provide
insights into the role aggregated α-crystallin plays in both the ageing eye lens, where the formation of
crystallin aggregates leads to lens opacification and cataract, and in extra-lenticular disorders such as
Alzheimer’s and Parkinson’s diseases and other amyloidosis, which are associated with the formation
of amyloid fibrillar aggregates.
2. Results
Nomenclature: In this work, α-crystallin purified from bovine lenses (i.e., containing both αA-
and αB-crystallin subunits) is referred to as α-crystallin, in order to delineate it from recombinant
human αB-crystallin.
2.1. α-Crystallin Amyloid Fibril Formation
α-crystallin (comprised of ~3:1 molar ratio of αA- to αB-crystallin) was extracted from bovine
lenses and purified as described by Chiou et al. (1979) [45]. α-crystallin amyloid fibrils were formed
by partial unfolding in denaturant at elevated temperature [4,46] and the transformation from native
to fibrillar state was confirmed by transmission electron microcopy (TEM) (Figure 1A,B). The fibrils
ranged in length from 20 nm to 1 µM and showed the characteristic morphologies previously described
for α-crystallin amyloid fibrils [46]. A number of smaller aggregates, either protofibrils or amorphous
aggregates, were also present.
2.2. Molecular Chaperone Activity of Native and Fibrillar α-Crystallin against Amorphous Aggregation
The chaperone activity of α-crystallin in native and amyloid fibrillar states was measured against
two amorphously aggregating target proteins: catalase destabilised by elevated temperature (60 ◦C)
and insulin destabilised by reduction at 37 ◦C [47]. Amorphous aggregation and amyloid fibril
formation occur in three main stages: a phase during which target protein unfolding and association
occurs; an exponential stage, where protein aggregates become large enough to scatter light; and a
plateau, where target protein aggregation is complete [48]. Protein aggregation was monitored via
light scattering at 340 nm. After approximately 40 min of incubation, both insulin and catalase reached
a plateau of light scattering, indicative of the completion of aggregation. The protection afforded
by the chaperone is apparent from the reduction in light scattering, and was quantified for further
statistical analysis using Equation (1). The chaperone activity against the aggregating target proteins
catalase and insulin is presented in Figure 1.
Native and fibrillar α-crystallin both demonstrated concentration-dependent chaperone protection
against the thermally-induced amorphous aggregation of catalase (Figure 1C,D). At 50 to 200 µg/mL
of chaperone (molar ratios between 0.4:1.0 and 1.5:1.0, chaperone:catalase), there was no significant
difference between native and fibrillar α-crystallin in protection against heat-induced amorphous
aggregation of catalase, e.g., at the highest concentration tested (i.e. a molar ratio of 1.5:1.0 α-crystallin:
catalase), a protection of 70 ± 7.2% and 66 ± 13.0% was observed for native and fibrillar α-crystallin,
respectively. There was a significant difference between the activity of native and fibrillar α-crystallin
over the concentrations tested, with catalase aggregation being inhibited to a greater degree by
native α-crystallin than fibrillar α-crystallin. Both native and fibrillar α-crystallin inhibited the
reduction-induced amorphous aggregation of insulin in a comparable, and concentration-dependent
manner (Figure 1E,F). In preventing insulin from aggregating, there was no statistical difference
between the protection provided by equivalent concentrations of native and fibrillar α-crystallin,
e.g., at a 1.0:1.0 molar ratio of α-crystallin to insulin, native and fibrillar α-crystallin inhibited insulin
aggregation by 83 ± 0.3% and 71 ± 5%, respectively.
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carboxymethylated (RCM) κ‐casein, 400 μg/mL incubated at 37 °C in 0.1 M sodium phosphate, 10 μM 
thioflavin T (ThT) for 12 h; (C,E,G) show representative profiles of light scattering; (D,F,H) show the 
percentage of protection provided by each chaperone, calculated  from  the difference between  the 
maximum  light scattering or  fluorescence of  the  target protein alone and  the  target protein  in  the 
presence of the stated concentrations of α‐crystallin. Data shown are means ± standard error (SE) of 
Figure 1. Fibril formation and chaperone activity of native and fibrillar α-crystallin. (A,B) Transmission
electron micrographs of α-crystallin fibrils formed in 1 M guanidine hydrochloride (GdnHCl), 0.1 M
sodium phosphate, pH 7.4 at 60 ◦C for 2 h, with red arrows indicating fibril structures. Scale bars are:
(A) 1 µm and (B) 200 nm; (C–H) Native and fibrillar α-crystallin chaperone protection of (C,D) catalase
at 400 µg/mL in 0.1 M sodium phosphate buffer at pH 7.4, undergoing thermal destabilisation at 60 ◦C;
(E,F) reduced insulin, 230 µg/mL in 0.1 M sodium phosphate buffer pH 7.4, at 37 ◦C in the presence of
10 mM 1,4-dithiothreitol (DTT); and (G,H) reduced and carboxymethylated (RCM) κ-casein, 400 µg/mL
incubated at 37 ◦C in 0.1 M sodium phosphate, 10 µM thioflavin T (ThT) for 12 h; (C,E,G) show
representative profiles of light scattering; (D,F,H) show the percentage of protection provided by each
chaperone, calculated from the difference between the maximum light scattering or fluorescence of the
target protein alone and the target protein in the presence of the stated concentrations of α-crystallin.
Data shown are means ± standard error (SE) of (D,F) three or (H) of six separate experiments; p-values
indicating significant difference from two-way ANOVA (Šidák post-hoc test) are: *** p < 0.001.
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2.3. Molecular Chaperone Activity of Native and Fibrillar α-Crystallin against κ-Casein Fibrillar Aggregation
To investigate further this potentially stress-dependent variation in chaperone activity, a third
target protein was examined. The milk protein κ-casein has a high propensity to form amyloid
fibrils when isolated from the other casein proteins [49,50]. The reduced and carboxymethylated
(RCM) form of κ-casein aggregates in a highly reproducible manner, leading to formation of amyloid
fibrils at physiological temperature and pH [50,51]. Both native and fibrillar α-crystallin showed
a concentration-dependent chaperone activity with regards to inhibiting fibril formation by RCM
κ-casein (Figure 1G,H). Against this target protein, significant differences in chaperone ability were
observed between the native and fibrillar forms of α-crystallin at each concentration tested. Fibrillar
α-crystallin was between 50% to 65% as effective at inhibiting RCM κ-casein fibril formation compared
to native α-crystallin, at each of the three molar ratios tested (0.3–0.5:1.0, α-crystallin: RCM κ-casein,
respectively). Thus, the fibrillar form of α-crystallin possesses chaperone activity comparable to that
of native α-crystallin for the two amorphously aggregating targets assayed. However, with regards
to the fibril-forming target protein, RCM κ-casein, the chaperone activity of fibrillar α-crystallin
was less than that of native α-crystallin, but it still protected against protein fibril formation in a
concentration-dependent manner.
2.4. Molecular Chaperone Activity of Native and Fibrillar α-Crystallin as Compared to Non-Chaperone Based
Amorphous and Fibrillar Aggregates
In order to further investigate the chaperone ability of destabilised α-crystallin, a stock of native
α-crystallin was prepared with the equivalent concentration of GdnHCl (1 M) used to prepare fibrillar
α-crystallin. This stock was stored at 4 ◦C for use in chaperone assays (‘α GdnHCl Native’) and
for fibril preparation (‘α Fibril’). TEM examination showed no observable difference in morphology
between native α-crystallin and GdnHCl-treated native α-crystallin, i.e., both appeared as roughly
spherical oligomers of approximately 15 nm in diameter (Figure 2A,B, oligomers highlighted with
yellow circles), and similar to what has been observed previously [52].
Following sample incubation under conditions conducive for amyloid fibril formation, all samples
were spin-filtered to remove any GdnHCl (where present). α-Crystallin amyloid fibrils appeared no
different in morphology after spin filtering and were highly comparable to non-spun α-crystallin
fibrils in length and concentration (Figures 1B and 2C, amyloid fibrils indicated by red arrows).
These structures have been previously characterised by our laboratory as amyloid in nature as they
exhibit thioflavin T and Congo red binding, and give a X-ray diffraction pattern characteristic of
the highly β-sheeted amyloid fibril structure [4]. In addition to the fibrillar structures, some small
spherical oligomers were present (yellow circles) as well as some large, mostly spherical aggregates
(green circles).
To examine whether the chaperone activity of aggregated α-crystallin was specific for the fibrillar
form, an amorphously aggregated form of α-crystallin was also prepared by incubation in 0.1 M
sodium phosphate buffer with 1 M GdnHCl at 90 ◦C for two hours (‘α Amorphous’). By TEM, this
species formed larger, mostly spherical, aggregates with some clumps of protein present (Figure 2D,
green circles), a morphology that is consistent with the findings of Burgio et al. [29] and previous
findings of our laboratory [53] where an increased size of α-crystallin oligomers at high temperatures
was demonstrated, with a tendency for those oligomers to clump into beads or strings.
To test whether chaperone activity was specific to α-crystallin amyloid fibrils, amorphous
aggregates and amyloid fibrils were prepared from non-chaperone active proteins. Amyloid fibrils
were formed from βH-crystallin (‘βH Fibril’) in the presence of trifluoroethanol (TFE) at low pH
under thermal stress conditions [4]. These fibrils are short and curly in nature, as seen in Figure 2E
(highlighted with blue arrows). Amorphous aggregates of aldehyde dehydrogenase (ADH) were
prepared in 0.1 M sodium phosphate, pH 7.4 with 1 M GdnHCl at 90 ◦C for 2 h (‘ADH Amorphous’),
and appeared as non-fibrillar amorphous protein clumps (Figure 2F).
Biomolecules 2017, 7, 67 6 of 20
Table 1 outlines the conditions used to prepare these protein species and the morphology of each
as observed by TEM. All samples, following incubation (at 4, 60 or 90 ◦C), were dialysed to remove
GdnHCl prior to assaying for chaperone activity. For ease of reference, the nomenclature in Table 1 is
used throughout this work. Within one hour of preparation, samples were used for chaperone activity
assays against insulin as a model of amorphous aggregation and RCM κ-casein as a model of fibrillar
aggregation (Figure 3). The assays highlight the ability of α-crystallin to act as a chaperone under
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Figure 2. Transmission electron microscopy (TEM) images of samples formed to assess the effects
of structural variation on the chaperone activity of α-crystallin: (A) α Native; (B) α GdnHCl Native;
(C) α Fibril; (D) α Amorphous; samples of α-crystallin. (E) βH Fibril; and (F) aldehyde dehydrogenase
(ADH) Amorphous samples. All samples were prepared as described in Table 1. Scale bars are 200 nm.
Features of importance are highlighted, including long amyloid fibrils (red arrows), curvilinear amyloid
fibrils (blue arrows) and spherical aggregates of ~15 nm in diameter (yellow circles) or larger spherical
aggregates (green circles).
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Table 1. α- and αB-crystallin species formed for chaperone assessment of structural variants.
Treatment Protein
Incubation Conditions
Buffer pH Temp. (◦C) Time (h) Morphology Figure
α Native α-Crystallin 0.1 M sodium phosphate 7.4 4 2 Spherical aggregates ~15 nm in diameter 2A
α GdnHCl Native α-Crystallin 1 M GdnHCl, 0.1 M sodium phosphate 7.4 4 2 Spherical aggregates ~15 nm in diameter 2B
α Fibril α-Crystallin 1 M GdnHCl, 0.1 M sodium phosphate 7.4 60 2 Long fibrils, (20 nm–1 µm in length), plus
short fibrils and/or spherical aggregates
2C
α Amorphous α-Crystallin 1 M GdnHCl, 0.1 M sodium phosphate 7.4 90 2 Larger spherical aggregates ~30 nm in
diameter, singly and in clumps
2D
βH Fibril βH-Crystallin H2O with 10% TFE 2 60 18 Short, curly fibrils, 20 nm to 200 nm in length 2E
ADH Amorphous ADH 1 M GdnHCl, 0.1 M sodium phosphate 7.4 90 2 Large non-fibrillar protein clumps 2F
αB Native αB-Crystallin 0.1 M sodium phosphate 7.4 4 2 Spherical aggregates ~15 nm in diameter 4A
αB GdnHCl Native αB-Crystallin 1 M GdnHCl, 0.1 M sodium phosphate 7.4 4 2 Spherical aggregates ~15 nm in diameter 4B
αB Fibril αB-Crystallin 1 M GdnHCl, 0.1 M sodium phosphate 7.4 60 2 Long fibrils, (>1 µm in length) 4C
αB Amorphous αB-Crystallin 1 M GdnHCl, 0.1 M sodium phosphate 7.4 90 2 Larger spherical aggregates ~30 nm in
diameter, singly or in row-like clumps
4D
ADH: aldehyde dehydrogenase; GdnHCl: guanidine hydrochloride; Temp.: temperature; TFE: trifluoroethanol.
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Figure 3. Chaperone protection provided by native, fibrillar and amorphous α-crystallin species against the (A) amorphous aggregation of reduced insulin, 250 µg/mL
in 0.1 M sodium phosphate, pH 7.4 and 20 mM DTT at 37 ◦C (0.9 chaperone: 1.0 insulin on a molar basis); and (B) fibrillar aggregation of RCM-κ-casein, 400 µg/mL
incubated at 37 ◦C for 22 h in the presence of various native, amorphous and fibrillar chaperone species (0.5 chaperone: 1.0 RCM κ-casein on a molar basis) and
monitored via ThT fluorescence. The percentage of protection provided by each chaperone is calculated from the difference between the maximal light scattering or
fluorescence of the target protein alone and the target protein in the presence of the stated concentrations of α-crystallin. Results are mean ± SE of the percentage
protection given by chaperones for three experiments; p-values, derived by one-way ANOVA with Tukey post-test, are * p < 0.05.
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Both α Native and α Fibril exhibited equivalent chaperone activity in preventing the
reduction-induced aggregation of insulin (Figure 3A). The overall chaperone activity for all treatments
was consistently lower compared to earlier assays, most likely as a result of protein loss during
the spin filter process (used for all samples to remove GdnHCl where present). α GdnHCl Native
and α Amorphous both had enhanced chaperone activity compared to α Native, whereas both βH
Fibril and ADH Amorphous species demonstrated no chaperone activity (Figure S1A). α Amorphous
exhibited enhanced chaperone activity compared to α Native, which may be responsible for the
chaperone activity of the α Fibril sample, as it contained both amyloid fibrils and amorphous aggregates
(Figure 2C). The enhanced activity of α-crystallin in the presence of GdnHCl has been demonstrated
previously [26], where an intermediate structure was proposed to have enhanced chaperone activity.
Furthermore, after urea denaturation, α-crystallin can refold into oligomers with increased chaperone
activity, coincident with an increase in surface exposed hydrophobicity [30].
When investigating inhibition of the amyloid fibril formation of RCM κ-casein, all native and
aggregated α-crystallin species (α Native, α GdnHCl Native, α Fibril and α Amorphous) acted
with similar chaperone efficacy (Figure 3B). In contrast, there was no chaperone activity exhibited
by aggregates of non-chaperone proteins, including βH Fibril and ADH Amorphous (Figure S1B).
In fact, both non-chaperone species caused a slight increase in ThT fluorescence associated with fibril
formation, possibly through a molecular crowding effect, with the presence of additional protein
promoting amyloid fibril assembly by enhancing self-association. Thus, all α-crystallin species (native,
previously destabilised, amyloid fibrillar and amorphous aggregates) retain chaperone activity against
RCM κ-casein aggregation.
Unlike the activity of α-crystallin species against amorphous insulin aggregation, there was
no significantly enhanced protection provided by amorphous aggregates of α-crystallin, making it
difficult to determine if the chaperone activity of α Fibril is the effect of the amyloid fibrils themselves
or of the amorphous aggregates present in this sample (or a combination of both). As observed with
amorphous aggregation at 37 ◦C, there was no chaperone activity from non-chaperone aggregates
(fibrillar or amorphous, Figure S1B), indicating that the chaperone activity exhibited by aggregated
α-crystallin species is not due to their exposed hydrophobicity.
The ability of destabilised and amorphous aggregates of α-crystallin to act as chaperones makes it
unclear whether α-crystallin fibrils actually retain chaperone activity. It is possible that the observed
chaperone activity of samples containing α-crystallin fibrils is due to the heightened activity (in some
cases, for example against reduced insulin) of α-crystallin amorphous aggregates which are also
present within these samples (Figure 2C). While the ability of amorphous aggregates of α-crystallin to
act effectively as a molecular chaperone is of interest in itself, and will be discussed in detail below,
a clearer understanding of whether α-crystallin amyloid fibrils can act as molecular chaperones is
desired, hence a study of the chaperone ability of αB-crystallin was undertaken.
2.5. Chaperone Activity of αB-Crystallin Fibrils and Other Species
αB-crystallin shows similar chaperone efficaciousness to α-crystallin in vitro at 37 ◦C. Previous
work in our laboratory has shown that amyloid fibrils, as defined by the X-ray fibre diffraction pattern,
formed from recombinant αB-crystallin contain less than 5% amorphous aggregates, i.e., much less
than is present in α-crystallin fibrillar samples [46]. Thus, αB-crystallin was selected for use in the
same assays to those already performed on α-crystallin. The higher purity of αB-crystallin fibrils arises
from less native protein and fewer amorphous aggregates, which enables simpler interpretation of the
effects of fibril formation on the chaperone activity of αB-crystallin. For comparison and as controls,
identical samples to those assessed for α-crystallin were prepared from αB-crystallin, i.e., αB Native;
αB GdnHCl Native; αB Fibril; and αB Amorphous, as were the non-α-crystallin controls βH Fibril;
and ADH Amorphous (Table 1).
Spin filtering to remove GdnHCl (where present) was again performed on all samples. All species
were then examined by TEM prior to chaperone assessment (Figure 4). As before, fibril structures are
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shown with red arrows and aggregates are highlighted with yellow and green circles. αB-crystallin
species were almost identical in appearance to those of α-crystallin (Figures 2 and 4), with the exception
of the αB Fibril sample, which featured amyloid fibrils over 1 µm in length with almost no amorphous
aggregates present (Figure 4C). There were visibly fewer amorphous structures present in the αB
Fibril sample when compared to the α Fibril sample (Figures 2C and 4C), again consistent with what
has been observed previously [4,46]. The chaperone ability of these species was assessed against the
reduction-induced amorphous aggregation of insulin and RCM κ-casein amyloid fibril aggregation,




induced aggregation of  insulin  (Figure 3A). The overall chaperone activity  for all  treatments was 
consistently lower compared to earlier assays, most likely as a result of protein loss during the spin 
filter process  (used  for all  samples  to  remove GdnHCl where present).  α GdnHCl Native and  α 
Amorphous both had enhanced chaperone activity compared to α Native, whereas both βH Fibril 
and ADH Amorphous  species  demonstrated  no  chaperone  activity  (Figure  S1A).  α Amorphous 
exhibited  enhanced  chaperone  activity  compared  to  α Native, which may be  responsible  for  the 
chaperone  activity  of  the  α  Fibril  sample,  as  it  contained  both  amyloid  fibrils  and  amorphous 
aggregates (Figure 2C). The enhanced activity of α‐crystallin  in the presence of GdnHCl has been 











similar  chaperone  efficacy  (Figure  3B).  In  contrast,  there was no  chaperone  activity  exhibited by 
aggregates of non‐chaperone proteins,  including βH Fibril and ADH Amorphous  (Figure S1B).  In 
fact, both non‐chaperone species caused a slight increase in ThT fluorescence associated with fibril 
formation, possibly  through a molecular crowding effect, with  the presence of additional protein 
promoting  amyloid  fibril  assembly  by  enhancing  self‐association.  Thus,  all  α‐crystallin  species 
(native,  previously  destabilised,  amyloid  fibrillar  and  amorphous  aggregates)  retain  chaperone 
activity against RCM κ‐casein aggregation. 
Unlike the activity of α‐crystallin species against amorphous insulin aggregation, there was no 




Figure 4. TEM images of αB-crystallin species formed to assess the effects of structural variation on
chaperone activity: (A) αB Native; (B) αB GdnHCl Native; (C) αB Fibril; and (D) αB Amorphous.
All samples were prepared as described in Table 1. Scale bars are 200 nm. Features of importance
are highlighted, including long amyloid fibrils (red arrows) and spherical aggregates of ~15 nm in
diameter (yellow circles) or larger spherical aggregates (green circles).
Destabilised forms of αB-crystallin, including the GdnHCl-treated native protein and both fibrillar
and amorphous aggregates, prevented both insulin amorphous aggregation and RCM κ-casein amyloid
fibril formation, as summarised in Figure 5. For both target proteins, there was no statistically
significant difference in chaperone activity of αB Fibril and αB Native. As observed for α-crystallin
amorphous aggregates, the αB Amorphous sample was significantly more effective against insulin
amorphous aggregation (over three times as effective as αB Native, Figure 5A), yet had equivalent
activity to native αB-crystallin with regards to inhibiting RCM κ-casein amyloid fibril formation
(Figure 5B). The increased ability of amorphous α-crystallin samples to inhibit insulin aggregation
thus appears to be specific to that target protein. Furthermore, it is unlikely to be an effect of enhanced
exposed hydrophobicity of this species, as ADH amorphous aggregates and βH crystallin amyloid
fibrils exhibited no chaperone activity against these target proteins (Figure S2).













It  is well  recognised  that α‐crystallin maintains  chaperone activity even under  conditions of 
structural  change. Thus,  the  chaperone  ability of  α‐crystallin  is  enhanced when  it  is  structurally 
perturbed or partially unfolded, i.e., under conditions of increased temperature or GdnHCl exposure 
[24–26,54,55].  Furthermore,  a  range  of  other  treatments  and  conditions  enhance  the  chaperone 









proteins, with  regards  to  its  capacity  to  inhibit  the  reduction‐induced amorphous aggregation of 
insulin and  fibrillar aggregation of RCM  κ‐casein.  In both  cases,  the  α‐crystallin  species  retained 
chaperone activity whilst non‐chaperone based amyloid fibrils and amorphous aggregates provided 
no  protection  to  the  aggregating  proteins.  It  is  extremely  unlikely,  therefore,  that  the  observed 
chaperone activity is due to generic chaperone activity of exposed hydrophobic regions on fibrils or 
amorphous  aggregates.  It  is  possible  that  some  of  the  observed  chaperone  action  arises  from 





of  these  factors  argues  against  dissociated  forms  of  α‐crystallin  being  solely  responsible  for  the 
observed chaperone action. Instead, it is concluded that part, if not all, of the chaperone ability of 
amyloid  fibrillar and amorphous aggregates of α‐crystallin,  is due  to  the chaperone activity of α‐
crystallin  being  retained  upon  aggregation  to  different  structural  forms.  This  is  consistent with 
previous  findings  from our  laboratory, which demonstrated  that  α‐crystallin  immobilised onto a 
solid‐phase support (i.e., when no dissociated species were present) had enhanced chaperone ability 
Figure 5. Chaperone protection provided by native, fibrillar and amorphous αB-crystallin species
against the (A) amorphous aggregation of insulin, 250 µg/mL at 37 ◦C in 0.1 M sodium phosphate,
20 mM DTT, pH 7.4 (0.9 chaperone: 1.0 insulin on a molar basis); and (B) fibrillar aggregation of
RCM κ-casein 400 µg/mL, 10 µM ThT at 37 ◦C, pH 7.4 (0.5 chaperone: 1.0 RCM κ-casein on a molar
basis). The percentage of protection provided by each chaperone is calculated from the difference
between the maximal light scattering or fluorescence of the target protein alone and the target protein
in the presence of the stated concentrations of αB-crystallin. Results are mean ± SE of the percentage
protection given by chaperones for three experiments; p-values, derived by one-way ANOVA with
Tukey post-test, are ** p < 0.01.
3. iscussion
It is ell recognised that α-crystallin aintains chaperone activity even under conditions of
structural change. Thus, the chaperone ability of α-crystallin is enhanced hen it is structurally
perturbed or partially unfolded, i.e., under conditions of increased temperature or GdnHCl
exposure [24–26,54,55]. Furthermore, a range of other treatments and conditions enhance the
chaperone activity of α-crystallin, including elevated pressure, the presence of various small
olecules and metal ions, and some post-translational modifications, for example the mimicking
of phosphorylation [47,56–59]. Remarkably, α-crystallin retains some of its chaperone activity even
when dissociated and severely structurally destabilised at low pH [60]. The work presented herein
demonstrates that, even after undergoing major structural rearrangement into amyloid fibrils or
amorphous aggregates, α-crystallin retains significant chaperone activity. Consistent with these results,
the high-molecular weight (HMW) form of α-crystallin isolated from aged bovine lenses, which has an
altered structure compared to the native form of the protein, retains some chaperone activity [44].
The chaperone activity of α-crystallin species as co pared ith various aggregated control
proteins, ith regards to its capacity to inhibit the reduction-induced a orphous aggregation of
insulin and fibrillar aggregation of RC κ-casein. In both cases, the α-crystallin species retained
chaperone activity whilst non-chaperone based amyloid fibrils and amorphous aggregates provided no
protection to the aggregating proteins. It is extremely unlikely, therefore, that the observed chaperone
activity is due to generic chaperone activity of exposed hydrophobic regions on fibrils or amorphous
aggregates. It is possible that some of the observed chaperone action arises from dissociated forms
of α-crystallin. However, we contend that the dissociated species cannot be responsible for all the
chaperone activity of the fibrillar α-crystallin samples. We base this on two factors: first, the majority
of species in the α Fibril sample, and the vast majority of the species in the αB Fibril sample, are
in the fibrillar form (as is apparent fro the TEM images); and second, the extent of the chaperone
action, which in some cases is similar to that of the native species. The combination of these factors
argues against dissociated forms of α-crystallin being solely responsible for the observed chaperone
action. Instead, it is concluded that part, if not all, of the chaperone ability of amyloid fibrillar and
a orphous aggregates of α-crystallin, is due to the chaperone activity of α-crystallin being retained
upon aggregation to different structural forms. This is consistent with previous findings from our
laboratory, which demonstrated that α-crystallin im obilised onto a solid-phase support (i.e., when no
dissociated species were present) had enhanced chaperone ability compared to native α-crystallin [61].
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Thus, for α-crystallin and αB-crystallin, the structural changes that occur in amyloid fibril formation
do not necessarily result in a loss of chaperone function.
The ability of fibrillar αB-crystallin to act as a molecular chaperone has in vivo relevance, both
within and outside the lens where αB-crystallin is found extensively. The conversion into amyloid
fibrils of a protein from its native state (whether structured or not) requires a dramatic alteration in
structure, and conceptually, it would be considered unlikely that biological function is retained after
such structural perturbation. In a related context, functional amyloid comprises protein aggregates
which exhibit biological activity whilst adopting the cross β-sheet structure characteristic of amyloid
fibrils [36,41,62,63]. Unlike α-crystallin fibrils, which occur as a mixed population of amyloid fibrils and
amorphous aggregates, αB-crystallin amyloid fibrils are formed with very few amorphous aggregates
present. Furthermore, against RCM κ-casein amyloid fibril formation, αB-crystallin amyloid fibrils
acted with enhanced activity, while amorphous aggregates of αB-crystallin had equivalent chaperone
ability to native αB-crystallin.
Significant parts of the amino acid sequences of both αA-crystallin and αB-crystallin are
potentially amyloidogenic [15]. They are primarily located in the central, conserved β-sheet-rich
α-crystallin domain (ACD) and are absent in the unstructured and relatively flexible C-terminal region.
The N-terminal region that flanks the ACD is also relatively unstructured, and has very few regions of
potential propensity to form amyloid fibrils. The C-terminal region, particularly the highly flexible
last 10 to 12 amino acids in both subunits, plays a role in solubilising the protein and both the N-
and C-terminal regions mediate interactions between the chaperone protein and its targets during
chaperone action [10,15,27]. Notably, the region of αA-crystallin encompassing residues 71 to 88 in
the ACD is both chaperone active as an isolated peptide and highly amyloidogenic [64]. The peptide
loses its fibril-forming propensity, whilst maintaining chaperone activity, when coupled to the highly
flexible C-terminal extension of αA-crystallin [64]. Conceivably, the similar properties that govern
the interaction and binding of α-crystallin to an unfolding target protein during chaperone action are
present during the mutual interaction to form fibrillar aggregates. The flexible C-terminal extension of
αB-crystallin is not incorporated into the fibril core; it maintains its intrinsic disorder [46] and as such
is available to mediate interactions between aggregated, fibrillar α-crystallin and other proteins.
The lens is a unique organ; it continues to grow throughout life yet lacks a blood supply
and exhibits no protein turnover. As such, the crystallin proteins in its centre are as old as the
individual [1,2]. To maintain lens transparency and the high refractive index necessary for vision,
the crystallins must remain stable and in solution. With age, extensive modification occurs to
the crystallins, i.e., deamidation, racemisation, phosphorylation, truncation, glycation etc. which
collectively affect their structure, solubility and potentially lead to precipitation and lens opacification
and cataract formation. The two α-crystallin subunits are particularly subjected to modification and
large-scale aggregation into HMW species. In fact, there is little, if any, intact α-crystallin remaining in
the normal, transparent human lens after 40 years of age [44,65]. Thus, our observation of the retention
of chaperone activity in heavily structurally modified (including amyloid fibrillar) α-crystallin is
consistent with the in vivo behaviour of modified α-crystallin in older, non-cataract (transparent)
lenses, in being a functioning chaperone to prevent crystallin aggregation [44]. It is also compatible
with the notion that aged α-crystallin in the lens may adopt an amyloid fibrillar structure [4,46],
in addition to forming amorphous aggregates, and that both retain some chaperone ability.
4. Materials and Methods
4.1. Materials
Alcohol dehydrogenase (ADH), κ-casein, catalase and insulin were obtained from Sigma Chemical
Co. (St. Louis, MO, USA). 1,4-dithiothreitol (DTT) and thioflavin T (ThT), were also purchased
from Sigma. All other chemical reagents were purchased from AJAX Finechem (Cheltenham, VIC,
Australia). Clear and µClear 96-well plates were obtained from Greiner Bio-One (Kremsmünster,
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Austria). ThinSeal was purchased from Excel Scientific Inc. (Victorville, CA, USA). Supor (0.2 µm)
syringe filters and Macropep 10 kDa spin tubes were obtained from Pall Life Sciences (Port Washington,
NY, USA). Formvar and carbon coated nickel electron microscopy grids were purchased from Pro Sci
Tech (Kirwan, QLD, Australia).
Bovine eye lenses were supplied by local abattoirs (T. & R. Pty. Ltd., Murray Bridge,
South Australia and CMP Canterbury Ltd., Ashburton, New Zealand). Escherichia coli containing
the plasmid vector pET20b(+) with the human wild type αB-crystallin gene previously inserted was
obtained from Prof. Wilbert Boelens, Radboud University, The Netherlands.
4.2. Methods
4.2.1. Bovine Crystallin Protein Extraction
Bovine crystallin proteins were extracted using standard methods, adapted from Carver et al. [44].
Multiple lenses were homogenised using a manual homogeniser in 3 mL buffer per lens, with the
buffer containing 50 mM Tris pH 7.2, 1 mM DTT and 0.04% NaN3. The homogenate was centrifuged
at 13,000× g for 30 min at room temperature. The supernatant, or crude crystallin stock, was stored
at −20 ◦C.
4.2.2. Bovine Crystallin Separation
Extracted crystallin proteins were separated using size exclusion chromatography (SEC).
Separation was performed using an AKTA FPLC (Amersham Biosciences, Little Chalfont, UK).
Aliquots of homogenate (1 mL) were run over a Sephacryl 300 Highprep 26/60 column (Amersham
Biosciences). The composition of semi-purified crystallin stocks was assessed using sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) with a wide range marker (Sigma) and only
non-contaminated samples used for further assays.
4.2.3. Expression and Purification of Human αB-Crystallin
Protein expression was initiated by plating and streaking out a small amount of thawed
vector-containing E. coli onto an ampicillin imbued agar plate. The culture plate was incubated
at 37 ◦C overnight to allow colonies to develop. Once colonies over the size of 2 mm were present,
the plate was placed to 4 ◦C and stored for up to two weeks. Only individual colonies were selected
for further culture and large-scale protein expression.
Large scale protein expression, also following the methods of [48], involved the transfer of
an individual E. coli colony (containing the plasmid vector) to 50 mL lysogeny broth (LB) media
with ampicillin (50 ng ampicillin:1 mL), culture was then grown at 37 ◦C with shaking overnight.
The cultured media was then distributed between 2 L of LB media (without ampicillin) and culturing
at 37 ◦C with shaking continued. Once the E. coli had grown adequately, with an optical density at
600 nm between 0.6 and 1.0, protein expression was induced by the addition of 0.25 mM isopropyl
β-D-1-thiogalactopyranoside. The E. coli was incubated for a further three to four hours (as above) to
allow protein expression to occur. Culture flasks were then removed from the incubator and the cells
were centrifuged at 5000× g for 20 min to form a cell pellet. The supernatant was discarded and the
cell pellet collected, weighed and stored at −20 ◦C until cell lysis and protein purification (a maximum
of one month).
The E. coli cell pellet was defrosted by resuspension in an ice-cold buffer of 50 mM Tris and 100 mM
NaCl at pH 8, using 3 mL of buffer per gram of cell pellet (gcp). To this was added phenylmethane
sulfonyl fluoride (2 µL of 0.5 M stock per gcp), lysozyme (0.8 mg per gcp) and deoxycholic acid
(4 mg per gcp). The cell lysis mixture was then placed at room temperature and gently shaken for
45 min. DNA was broken down by addition of DNAse I (2 µL of a 10 mg/mL stock per gcp) with
shaking at room temperature until the mixture lost viscosity. Metals were removed by the addition of
ethylenediaminetetraacetic acid (EDTA) (8 µL of 250 mM stock per gcp) and the waste components
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removed by centrifugation at 12,000× g for 30 min at 4 ◦C. The un-purified protein fraction, contained
in the supernatant, was collected.
Purification of recombinant human αB-crystallin from the cell lysis supernatant was achieved
using anion exchange chromatography. Five mg of DTT and 36 µL of polyethylenimine per gcp were
added to the cell lysis supernatant and incubated at room temperature with constant mixing for 20 min.
Waste proteins were removed by centrifugation at 13,000× g for 30 min at 4 ◦C, with the αB-crystallin
containing supernatant collected and loaded onto a diethylaminoethyl (DEAE) column (XK 26, packed
with Sepharose Fast Flow gel, Amersham Biosciences) which had been equilibrated with three column
volumes of 20 mM Tris, 1 mM EDTA at pH 8. αB-crystallin was removed via a salt gradient using
a buffer of 20 mM Tris, 1 mM EDTA and 1 M NaCl. αB-crystallin was the primary peak eluted and
contained a pure band of an approximately 20 kDa protein. Protein purity was assessed by SDS-PAGE.
4.2.4. Aggregate Formation for Use as Molecular Chaperones
Refolded Aggregate Formation for Use as Molecular Chaperones
α- and αB-crystallin refolded oligomers were formed to examine their molecular chaperone
ability. 3 mg/mL of each protein was reconstituted into 0.1 M sodium phosphate, 1 M GdnHCl and
incubated at 4 ◦C for two hours. To allow refolding of subunits the removal of GdnHCl was achieved
as outlined below.
Amorphous Aggregate Formation for Use as Molecular Chaperones
Three mg/mL each of α- and αB-crystallin was reconstituted into 0.1 M sodium phosphate, 1 M
GdnHCl and incubated at 90 ◦C for two hours. Where required, samples were treated using the method
for removal of GdnHCl (see below) to produce equivalent conditions and thus allow for comparison
of samples.
Amyloid Fibril Formation by α-Crystallin Using GdnHCl
α- and αB-crystallin amyloid fibrils were formed using methods adapted from Meehan et al.
(2004) [4]. Three mg/mL of each protein was reconstituted into 0.1 M sodium phosphate, 1 M GdnHCl
and incubated at 60 ◦C for two hours. Where required, samples were treated using the method for
removal of GdnHCl (see below) to produce equivalent conditions and thus allow for comparison
of samples.
4.2.5. Monitoring Protein Aggregation
Induction of Amorphous Aggregation
Amorphous aggregation of the target protein was induced in two ways, either by temperature
destabilisation or by the reduction of disulfide bonds [58,66]. Protein precipitation increases the
turbidity of solutions which was monitored by light scattering at a wavelength of 340 nm [58].
Data were acquired using a Fluostar Optima plate reader (BMG Lab technologies, Mornington, VIC,
Australia). In this work, all proteins (target and chaperone) were prepared in 0.1 M sodium phosphate
at pH 7.4 and filtered with 0.2 µm filter immediately prior to further sample preparation (either
formation into amorphous or fibrillar aggregates). Assays were run in clear 96-well plates, using a
sample volume of 200 µL/well. No agitation of solutions was used.
Light Scattering Assessment of Thermally Induced Amorphous Aggregation
Catalase was used to assess the ability to inhibit temperature-induced (in this case 60 ◦C)
amorphous aggregation. Assay samples included: buffer alone (0.1 M sodium phosphate at pH 7.4);
catalase in buffer; chaperone protein in buffer; and catalase and chaperone protein in buffer. All samples
were run in duplicate, and the activity of each chaperone protein assessed over three to six separate
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experiments. Aggregation was determined as maximum change in light scattering at 340 nm ± 10 nm
between the initial time-point and the final time-point. Final time-points were determined by a plateau
in light scattering (i.e., completion of protein precipitation by catalase at 40 min). Results displayed are
the mean ± standard error (SE) for all replicates.
Light Scattering Assessment of Disulfide-Bond Reduction Induced Amorphous Aggregation
Insulin was used to assess the ability to inhibit the reduction-induced amorphous aggregation of
a target protein. Assay samples included: buffer with DTT (0.1 M sodium phosphate at pH 7.4, 20 mM
DTT); insulin in buffer with DTT; chaperone protein in buffer with DTT; and insulin and chaperone
protein in buffer with DTT. Assays were performed at 37 ◦C Aggregation was assessed as per the
catalase aggregation assays, with a plateau in light scattering at 40 min for all assays. Results displayed
are the mean ± SE for all replicates.
4.2.6. Characterisation of Amyloid Fibril Formation
Amyloid Fibril Formation by RCM κ-Casein
RCM κ-casein was reconstituted in 0.1 M sodium phosphate and 10 µM ThT, pH 7.4. Amyloid
fibrils were formed upon incubation at 37 ◦C with linear shaking at 115 rpm for up to 20 h, following
the method of Thorn et al. (2005) [50].
Thioflavin T Assay of Amyloid Fibril Formation
ThT assays were performed in situ by a method adapted from Nielsen et al. (2001) [67]. Samples
were incubated with 10 µM ThT in µClear 96-microwell plates using a sample volume of 100–200 µL
per well. Plates were sealed with ThinSeal (Excel Scientific Inc., Victorville CA, USA) to prevent
evaporation, and incubated at 37 ◦C with or without shaking. Fluorescence was measured at regular
intervals using Fluostar Optima plate reader (BMG Lab technologies, Australia) with a 440/490 nm
excitation/emission filter set (±10 nm) until a plateau in fluorescence was obtained (different for each
target protein). All proteins (target and chaperone) were prepared in 0.1 M sodium phosphate at
pH 7.4 and filtered with 0.2 µm filter immediately prior to use (i.e., prior to formation into potential
chaperone structures). Sample volume was 200 µL/well and no agitation of solutions was used.
To allow comparison between increases in ThT fluorescence, each curve was normalised relative to
the initial fluorescence intensity (change in fluorescence) to eliminate artefacts resulting from the ThT
binding propensity of the native target peptide or protein. The maximum change in fluorescence
(between the initial time-point and the final time-point) was used for all further calculations, and the
mean ± SE of three replicates was used for all statistics and graphs.
Transmission Electron Microscopy
TEM was performed as described by Thorn et al. [50]. Samples were prepared on formvar and
carbon-coated nickel electron microscopy grids. Protein samples were diluted to 0.5 or 1 mg/mL and
2 µL was deposited on each grid. The grid was rinsed three times with 10 µL of H2O, negatively
stained with 10 µL of uranyl acetate (2% w/v) and dried with filter paper. Samples were analysed
under magnifications of 20,000× to 130,000×, using an excitation voltage of 120 kV on a Philips Technai
100 transmission electron microscope (FEI, Hillsborough, OR, USA). For all samples, multiple regions
(at least three) on the grid were examined to assess structure dispersal. For initial nanofibre assessment,
at least three separate samples were examined. For monitoring of chaperone activity against known
amyloid or amyloid-like fibril forming proteins, TEM assessment was performed on target protein
alone and target protein in the presence of chaperone for three separate experiments.
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Removal of GdnHCl from α-Crystallin Samples for Use as Molecular Chaperones
To remove GdnHCl from solutions of α-crystallin aggregate species, native protein (GdnHCl-free
control), GdnHCl unfolded protein, amorphous aggregates or amyloid fibrils were spun at 14,000× g
in Macropep 10 kDa spin tubes (Merck Millipore, Bayswater, VIC, Australia) for three consecutive
30 min washes (with 0.1 M sodium phosphate buffer, pH 7.4) and then resuspended into an equivalent
volume of 0.1 M sodium phosphate buffer, pH 7.4.
Quantification of Molecular Chaperone Activity
Chaperone activity was determined from the light scattering and ThT variables measured as
described above. The percentage of protection provided by a given sample is derived from the
difference between the maximum change in light scattering or ThT fluorescence for the target protein
alone and in the presence of the chaperone, i.e., the maximum change in light scattering or ThT
fluorescence for the target protein is judged to be 100% aggregated, upon addition of an active
chaperone to the target protein a drop in maximum light scattering or ThT fluorescence would be
observed, this equates to less target protein aggregated. The following equation (Equation (1)) [58]
was used to quantify the protection provided by each chaperone:
Percentage Protection =
(




where Max is the maximal change observed in light scattering or ThT fluorescence between the initial
time-point and end time-point of the assay. All statistical analysis of percent protection results was
performed on the mean percent protection value of three to six replicates. Data are presented as
mean ± SE where p < 0.05 was considered significant.
5. Conclusions
For over 25 years, α-crystallin has been recognised as a molecular chaperone of importance
in the prevention of cataract and other protein aggregation disorders [9,48]. The primary role of
α-crystallin as a molecular chaperone is to inhibit protein aggregation under conditions of cellular
stress. As a result, the ability of α-crystallin to function effectively as a chaperone when structurally
perturbed is a desirable biological quality. In this work, it has been established that both α-crystallin
and αB-crystallin retain chaperone activity following destabilisation by GdnHCl, and when forming
amorphous aggregates and amyloid fibrils. Indeed, αB-crystallin has enhanced chaperone activity
after modification into amyloid fibrils. Thus, α-crystallin’s role as a molecular chaperone in vivo is
likely to be maintained even under conditions where it does not sustain its native conformation, and is
converted into other structural forms, including amyloid fibrils. Indeed, the structured ACD region
of αB-crystallin on its own has significant chaperone ability [68]. Thus, truncation of αB-crystallin
termini does not alter chaperone functionality. Accordingly, it may be proposed that nature has
engineered α-crystallin to be malleable, both structurally and functionally. When in a fibrillar form,
α-crystallin exhibits properties of functional amyloid. In the lens, the retention of chaperone ability
of various non-native structural forms of α-crystallin has important implications. With ageing of the
lens, where there is no protein turnover, the large number of post-translational modifications that
occur to α-crystallin, with concomitant unfolding and potential aggregation (e.g., to form amorphous
and/or amyloid fibrils), may not alter significantly its ability to prevent the unfolding and potential
aggregation of the other crystallins. Such retention of chaperone function after modification and/or
aggregation would serve to protect the eye lens from opacification and cataract formation.
Supplementary Materials: The following are www.mdpi.com/2218-273X/7/3/67/s1, Figure S1: Chaperone
protection provided by native α-crystallin compared to non α-crystallin aggregates, Figure S2: Chaperone
protection provided by native αB-crystallin compared to non α-crystallin aggregates.
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